Rallybio Corporation

NASDAQ:RLYB

Biotechnology

Healthcare
$15.26 +0.03%

+$0.01 today

Market cap
$82.16M
Beta
-0.88
P/E (TTM)
-11.6
EPS (TTM)
-$1.37
52W Low $2.40High $17.57

Volume 0.03M

Average 0.25M

RLYB Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Rallybio CorporationNASDAQ: RLYB

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 98.6%

Gross margin was 98.6% in Q1 FY2026, down 1.4 pp from a year earlier. On a trailing-twelve-month basis it was 99.7%, up 7.2 pp year over year.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
98.6%-1.4 pp QoQ
Last fiscal yearDec 2025
89.3%-10.7 pp YoY
LTMMar 2026
99.7%+7.2 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.4 pp——
1 year-10.7 pp——
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
89.3%
Year-over-year change
-10.7pp

Gross Margin vs competitors

How RLYB compares with its peers on the latest reported figures

  • RLYB's LTM Mar 2026 gross margin of 99.7% is the 2nd highest of the 3 companies compared; the peer median is 99.7%.
  • Its year-over-year change of +7.2 pp is the highest of 2, against a peer median of +0.0 pp.
RLYB Competitors Peer median
Gross Margin for RLYB and competitors
Company Period LTM level YoY 3-year change
IBIOiBio, Inc.LTM Jun 2026100.0% +0.0 pp—
RLYBRallybio CorporationLTM Mar 202699.7% +7.2 pp—
QTTBQ32 Bio Inc.LTM Mar 202699.3% —-0.7 pp
BOLDBoundless Bio, Inc.FY2025— ——
Peer median (excluding RLYB) 99.7%+0.0 pp-0.7 pp

Competitors are the stored peer set for RLYB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000636K858K
Cost of Revenue109K167K150K131K92K
Gross Profit(109K)(167K)(150K)636K766K
Gross Margin———100.0%89.3%
Research & Development26.91M40.69M53.54M41.51M19.6M
Selling, General & Admin18.74M27.2M25.39M19.63M14.33M
Operating Expenses45.65M67.88M78.93M61.13M28.83M
Depreciation & Amortization109K167K150K131K92K
EBITDA(45.39M)(67.72M)(78.78M)(60.37M)(27.97M)
EBITDA Margin———-9491.4%-3260.1%
Operating Income(45.65M)(67.88M)(78.93M)(60.5M)(28.06M)
Operating Margin———-9511.9%-3270.9%
Interest Income54K1.96M6.15M4.22M2.19M
Interest Expense10K0000
Other Income / Expenses(1.37M)1.23M4.37M2.72M19.09M
Income Before Tax(47.01M)(67.73M)(74.56M)(57.78M)(8.98M)
Pre-Tax Margin———-9084.1%-1046.4%
Income Tax Expense0(1.08M)000
Net Income(47.01M)(66.65M)(74.56M)(57.78M)(8.98M)
Net Margin———-9084.1%-1046.4%
EPS (Basic)(11.68)(16.72)(14.72)(10.64)(1.59)
EPS (Diluted)(11.68)(16.72)(14.72)(10.64)(1.59)
Weighted Avg Shares4.02M3.98M5.06M5.44M5.63M
Weighted Avg Shares (Diluted)4.02M3.98M5.06M5.44M5.63M

Rallybio Corporation

NASDAQ:RLYB

Intrinsic Alpha fair value

Locked

Current Price

$15.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.